Jamie D. Matthews
Cambridge, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications
Establishing Patient-Derived Xenograft (PDX) Models of Lymphomas.
Journal: Methods in molecular biology (Clifton, N.J.)
Published: October 18, 2024
The anti-diabetic PPARγ agonist Pioglitazone inhibits cell proliferation and induces metabolic reprogramming in prostate cancer.
Journal: Molecular cancer
Published: June 24, 2024
Patient-derived xenograft models of ALK+ ALCL reveal preclinical promise for therapy with brigatinib.
Journal: British journal of haematology
Published: April 20, 2023
Targeting NRAS via miR-1304-5p or farnesyltransferase inhibition confers sensitivity to ALK inhibitors in ALK-mutant neuroblastoma.
Journal: Nature communications
Published: October 28, 2022
STAT3 couples activated tyrosine kinase signaling to the oncogenic core transcriptional regulatory circuitry of anaplastic large cell lymphoma.
Journal: Cell reports. Medicine
Published: September 25, 2022
Paediatric Burkitt lymphoma patient-derived xenografts capture disease characteristics over time and are a model for therapy.
Journal: British journal of haematology
Published: June 15, 2020
IL10RA modulates crizotinib sensitivity in NPM1-ALK+ anaplastic large cell lymphoma.
Journal: Blood
Published: October 18, 2019
Whole Exome Sequencing reveals NOTCH1 mutations in anaplastic large cell lymphoma and points to Notch both as a key pathway and a potential therapeutic target.
Journal: Haematologica
Published: September 19, 2019
The targetable kinase PIM1 drives ALK inhibitor resistance in high-risk neuroblastoma independent of MYCN status.
Journal: Nature communications
Published: February 05, 2019
Correction: Synergistic activation of pro-inflammatory type-2 CD8 + T lymphocytes by lipid mediators in severe eosinophilic asthma.
Journal: Mucosal immunology
Published: December 07, 2018
Last Updated: 09/26/2026